NASDAQ · Biotechnology · USD

Conexeu Sciences Inc. (CNXU) Stock Analysis

Conexeu Sciences Inc. (CNXU) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CNXU

$3.33

+$0.34 (+11.37%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CNXU with… →

CNXU Key Statistics

As of Oct 21, 2026

Trading

Open: $3.05
Previous Close: $2.99
Day's Range: 3.00–3.58
52-Week Range: 2.95–18.79
Volume: 416.32K

Valuation

Market Cap: $84.34M
P/E Ratio: unprofitable
EPS (ttm): −0.61

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$3.92M
Shares Outstanding: 28.21M

Dividend and dates

Avg Volume: 247.22K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Conexeu Sciences Inc. (CNXU) has a market capitalization of $84.34M.

In fiscal 2025, CNXU reported revenue of $0.00.

CNXU Revenue and Earnings by Fiscal Year

FY ends October

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$3.92M	—
2024	$0.00	−$471.87K	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$3.96M	−$3.92M	—
2024	$0.00	—	−$643.04K	−$471.87K	—

Annual figures as reported, in the company's reporting currency. As of October 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Conexeu Sciences Inc. (CNXU) is capitalised at $84.34M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for CNXU is $3.33, dated October 21, 2026. That is +$0.34 (+11.37%) against the previous close. Over the past 52 weeks the price has ranged from $2.95 to $18.79. The latest close sits 12.88% above that 52-week low.

Financial Health

In fiscal 2025, Conexeu Sciences Inc. reported revenue of $0.00. The same year closed with a net loss of $3.92M. Trailing earnings per share are −0.61.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

The record shows no dividend for CNXU.

So far in 2026 the total return is −74.52%.

Peer Comparison

Conexeu Sciences Inc. (CNXU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Conexeu Sciences Inc.	CNXU	$84.34M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Conexeu Sciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Conexeu Sciences Inc.

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.

Visit website →